Redhill Biopharma Ltd To Discuss The Opaganib Phase 2/3 COVID-19 Data Call Transcript
Good day, and welcome to the RedHill Biopharma's webcast on the opaganib Phase II/III data. (Operator Instructions)
At this time, I would like to introduce to the conference call RedHill's CEO, Dror Ben-Asher; Gilead Raday, RedHill's Chief Operating Officer; and Dr. Mark Levitt, RedHill's Medical Director Oncology.
Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.
This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to the business promotion and other efforts related to RedHill's commercialization activities and the initiation, timing, progress and results of RedHill's research, manufacturing, preclinical studies, clinical trials, marketing applications and approvals, if any, including the results and the clinical study of opaganib for the treatment of COVID-19.
These statements are only
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |